{"name":"Arvinas Inc.","slug":"arvinas-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":262600000,"revenueGrowth":-0.3,"grossMargin":0,"rdSpend":285200000,"netIncome":-80800000,"cash":717900000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","indication":"Prostate cancer","status":"phase_1"},{"name":"ARV-806","genericName":"ARV-806","slug":"arv-806","indication":"Metastatic castration-resistant prostate cancer","status":"phase_1"},{"name":"ARV-110","genericName":"ARV-110","slug":"arv-110","indication":"Prostate cancer","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ARV-393","genericName":"ARV-393","slug":"arv-393","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","phase":"phase_1","mechanism":"Androgen receptor inhibitor","indications":["Prostate cancer"],"catalyst":""},{"name":"ARV-806","genericName":"ARV-806","slug":"arv-806","phase":"phase_1","mechanism":"ARV-806 is a PROTAC (proteolysis targeting chimera) designed to degrade the androgen receptor (AR) in prostate cancer cells.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"ARV-110","genericName":"ARV-110","slug":"arv-110","phase":"phase_1","mechanism":"Selective androgen receptor degrader","indications":["Prostate cancer"],"catalyst":""},{"name":"ARV-393","genericName":"ARV-393","slug":"arv-393","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PWVJvZWpPZi1UbVZiN180OU1FTzNsc1BCTUhZSk1QNzFJcEZZSkVMTVdzakptRnFpOWVrX0hRQS1DOEtMX2ZjQThEZG1NdlRZYmVZb0k3bGlsR1hVMS1J?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill","headline":"ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNd0tJX1JoVVZVdDltcDdqSlp0aExUV004U2FWeXNjeHcwMXVhbG9Uc0ZYOTRkVnpLcmdOWGNtcXNibWdrZFl2ZWZxeEZURDY0ZlJFZmtsdnZoN09oZjhGRUlBSUhOVFJrSlktMnRtbnNfYU5yNFhKVXVuRmVKNWt4cUIwNEpkM1FOZmZXQ1JlWV9WQnFyeGI5dW1jS3p3YkVRYUJGVThKUERRTU1FLUNuRi1pcERublNKemZHdEF3UjNXbG9XWXlZLWY1aGR3RnE3TlBLS29KNzd5NERHZnF3UFIxRG9CZy0ySmprVmNmdnhGLXJFOGdwakp6c0hucHR3ZFFWb1JyQ1BlODdJMHV5eE5qSU8tYng4bVp5VEdSX0Y3Z09IanJlZTQxcTlwZw?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceu","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPLXFuTjFQRGZydnNJaHZCZjVQVzFpTVVkcmxyVkJJX1k0Tl9pamdSTWlWNFZNUGo1LTJPQnhvS3ZUZnRtYlJLNUVEMVk4M2FjbkRnUGhqWmhDYXNUZ0RMNmNyTDkxSzZ4Tkstb1dtQ05sRWNDb2ZxOTc1YzNSV2FUbkl6MUh0a05qWFNuUy05MFh1amU0anhELVlCZEF6YVRtWEpWXw?oc=5","date":"2026-02-25","type":"pipeline","source":"Yale Daily News","summary":"New CEO at local biotech firm is leading shift to early-stage drugs - Yale Daily News","headline":"New CEO at local biotech firm is leading shift to early-stage drugs","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPTU5MeGwybmpHNVhidG16MUhYOFRHYkY0WHlTN0J4bTVWS0VjNWtCc0JQV2pkZWVxbTNoRGZNYjQ4RWJCV0QzdkNTWnc0LTMyQnl0cjR2azZBV0d1c2FtMUlJRXp6S25ESXhjVEdfT0xTcko0M1ZXOHhtcFVOQmZSc3dobmdkOWphQUk2QWpudnh3QXFZcEJGa2t1QUVmZktQLXpYNVQwMlZfNktaZ3pfamdyRkJkZWxCNFcxX3NJVFM?oc=5","date":"2025-09-18","type":"pipeline","source":"Fierce Biotech","summary":"Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech - Fierce Biotech","headline":"Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPVGJjeGhMbndlVnNVNk5IVm5TUXFQUHFzT0FIUTBjSGRvakJ2VWFmUHJ3M3hONTFwTWNJNHl2UldMU2dBZmhXbEZvZEhiRTgtSnVnYkdkNWZOTDF0RFVDTVNiM0czX0NrUzZzYWM3UUxUc1M5dFR3TW02R3NXOWkzY2VqVDlNLUZVdWQ1ajdTYXpBc3ZzbWlUMUFwTTNTblNCWF9odGt6ejNEemdUOFlKdnR0eVJaMUcyLUZKbWlDXzgyOWZrS0pnbUxrcm91NFAwSldsbFEtTldlaUhTNnhfSlR3?oc=5","date":"2025-09-17","type":"pipeline","source":"Reuters","summary":"Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - Reuters","headline":"Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOZDVCXzIwQWJrbzFudXllUk9vNEhMLUxQaEhCbVNmSmFGZWZYZVlNTFJpVDNHUlFSVl9Kd1JxZHV5NXdMdlNJMjNXSzZ1NFQ3U2hETnVQbnRQdVkxSUZxQ2MzM0Nsc2FTLS1ma084Qkl2UkVoMDFYSjMyRXdhWDZneWpFdk9hMUtLcGY1Z0xNcERPUmxtcVNIajlQbUc4UTNKelhxWjlmX1pUMDZUdGhJN01KWk5Jdk56Y0xHa1dUQ2VVbGg2eUZ0SHBjQWdpRElRb21rUXZwTjdveUFl?oc=5","date":"2025-05-31","type":"pipeline","source":"Reuters","summary":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters","headline":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQMmc5NXQ0VWc5b2UxU1oxS1BFa3hGUk0xaDNhblhsNDlOZXJidXZQOWtGbU9qeDZ4WmhaTlJiMWxoY2VMcy05cWRsekt1Z2FmT1ZSVnExOHhyS21sc1BHUTBpRXNnWmhDRW5Yd2hsd0FrVlpUWjlhVlZ3M3hNc2hhbG1jLWE5LW8tVmJLaVlLMk1LaFdjSUtV?oc=5","date":"2025-05-27","type":"pipeline","source":"CT Insider","summary":"Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - CT Insider","headline":"Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5TdXdUTmM5ZTY3aS14am9vTGtZUHcyZ2NPbDJBTU9BRWFXQmtJSjlHU0ZBZkktMnFCM2t3WWE1VkoybW1Xcng3ZmJ4OUlWMk0zTnRtbU1Id3JNQWEwZl9BT0xLcHJiMDA0d1V4MDRB0gFyQVVfeXFMTWdIZjRGRjc3SElvODVfSnhrUHFmbWhCSW1GVlh5ZEpDdnZwc045aFNHcDJGeHJ5U2FXZlZLT0JZZ241SVJ5MU1HR0xJWVFqc3F5UXJmeGFNZ1h3blZTbVZGVGdlbEJlV0VtOW9GNXlsQlp3?oc=5","date":"2025-04-21","type":"pipeline","source":"koreabiomed.com","summary":"Korean pharma acclerates TPD and DAC development amid global interest in new drug madalities - koreabiomed.com","headline":"Korean pharma acclerates TPD and DAC development amid global interest in new drug madalities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYWdnMnZlYjZvUWpnRTVMMHNEZllaREtKdGoyMmhFSy1jdER3S0MtQllRZ2RhbDhLVG9ETElKY1lVT2VjclV3Z2pURmppV2JTMWVuOEZJMzlfM2Z4Ti01UUpRQi1MOTdPY1hucGo3MlV0WWEyZmw3azdXWlp2UXhsY2R6bjQ4clhyZTdmNW5mN1REZllNZEhUV3VQSGhzTU0?oc=5","date":"2025-03-11","type":"trial","source":"BioPharma Dive","summary":"Arvinas gets positive breast cancer data, but finds differentiation a hard sell - BioPharma Dive","headline":"Arvinas gets positive breast cancer data, but finds differentiation a hard sell","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQS1VPUFkyVlFLaGdKZTZRQjhNTXVZcXpXaHdXYnNsU0dPMjlNZGVqaUREQ09YcHhDakdYYUtQbmFfckpweDg0OVFnajEzUW55RC0tWXdDR1hveVVjSFNIa3l0c2FyMGxxY2ZMNFZEakJibmFQdzJTcVJ4U2VaZEpyZ0JCVjNKOHZDOGxLcS16T2drLXN5RHJoRlNYUTVuQnNu?oc=5","date":"2025-03-11","type":"deal","source":"Investor's Business Daily","summary":"Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily","headline":"Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQY3Y4WXZxOEptbmh6cHgzaXlqbXZmYnJZc1FQdmdGR0h6aVN6RUxUZ21waTA0YkpZNVR4MWpsTWppSXZnZ0RQazN3Umw1Y0xOMzZUdlg0SkV4Y01uWFNqaUVLWDVzelozLTl1ZHdiSm1iemJpbU1TYjZWQ2FlNG5hTjI2dVBra2pqaHNoOGwwRQ?oc=5","date":"2024-09-04","type":"pipeline","source":"Pharma Voice","summary":"Pharma’s ‘it’ therapy — a new drug class gaining steam - Pharma Voice","headline":"Pharma’s ‘it’ therapy — a new drug class gaining steam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQMGhOcWg4QjJQV1BrYWJuMklZNkRZWWtMOGxkYmFsNldPT1ZRbGctYlh5c2gxa3MyeFFqcjRGVXRxRzdBOEZiaTJERzNZSVVubUpyYV9nVEEtS0lVX29HaEJ0R0FEV0M1QWJkX184R0wwa0ZQTXNQTDV5MW0xTnMtbjF3eE9XQTQ1bWFhTERXV0c?oc=5","date":"2024-04-11","type":"trial","source":"Oncology Pipeline","summary":"Arvinas degraders get another vote of confidence | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Arvinas degraders get another vote of confidence | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":262600000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":262600000,"period":"2025-12-31"},{"value":263400000,"period":"2024-12-31"},{"value":263400000,"period":"2024-12-31"},{"value":78500000,"period":"2023-12-31"},{"value":78500000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":285200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-80800000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":717900000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}